Discovery and Basic Research
Mark Niosi
Principal Scientist
Pfizer Inc
Groton
Erica Schlesinger, Ph.D. (she/her/hers)
Vice President of Technical Development
SerĂ¡n Bioscience
Bend, Oregon
Optimizing in vitro ADME assays to Deliver Orally Bioavailable PROTACs
A significant challenge with oral bioavailability for large and complex molecules like PROTACs, lies in their propensity to experience poor intestinal absorption. Factors such as low membrane permeability, instability within the intestinal environment, and susceptibility to enzymatic degradation, all can hinder their ability to be orally bioavailable.
Learning objectives:
How useful are ADME properties for design and optimization of PROTACs
Opportunities of different analytical and in silico tools to advance drug design
Identify and resolve the challenges within in vitro ADME assays in drug discovery (DDI, PPB, Metabolic stability etc)